Acute myeloid leukemia(AML)is a heterogeneous malignancy with heterogeneity,and 35%-45%of patients are refractory to first-line treatment[e.g.,standard chemotherapy and hematopoietic stem cell transplantation(HSCT)]or...Acute myeloid leukemia(AML)is a heterogeneous malignancy with heterogeneity,and 35%-45%of patients are refractory to first-line treatment[e.g.,standard chemotherapy and hematopoietic stem cell transplantation(HSCT)]or relapse after treatment.Patients with refractory/relapsed(R/R)AML have a dismal prognosis and are ralely cured with conventional treatment(1),indicating the need for new therapeutic strategies to improve outcomes.展开更多
基金supported by the National Major Scientific and Technological Projects(No.2023ZD0501201)the Science and Technology Planning Project of Guangdong Province(No.2024A0505090015)+2 种基金the Clinical Research Project of Nanfang Hospital,Southern Medical University(No.2023CR007)the Science and Technology Project of Ganzhou City(No.GZ2024YLJ033)the National Natural Science Foundation of China(No.82170215)。
文摘Acute myeloid leukemia(AML)is a heterogeneous malignancy with heterogeneity,and 35%-45%of patients are refractory to first-line treatment[e.g.,standard chemotherapy and hematopoietic stem cell transplantation(HSCT)]or relapse after treatment.Patients with refractory/relapsed(R/R)AML have a dismal prognosis and are ralely cured with conventional treatment(1),indicating the need for new therapeutic strategies to improve outcomes.
